Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof

US6926896B2 · kind B2 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Klaus Bosslet · Marburg, DE
• Gerhard Seemann · Lahntal, DE
• Hans-Harald Sedlacek · Marburg, DE
• Bernhard Auerbach · Marburg, DE

Key dates

• Filing date: Dec 13, 1994
• Grant date: Aug 9, 2005
• Expiry date: Dec 13, 2014

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.